Total IL-33 levels were measured in the study as a surrogate of target engagement, and they appeared to have reached their maximum level/plateau by Day 61 in Part 2 (patients with CRSwNP) and Day 113 in Part 3 (patients with AD). This evidence concerns the gene IL33 and Alzheimer disease.